Executive Director, Head of Real-World Analytics and Programming
Revolution Medicines
Summary
The Executive Director, Head of Real-World Analytics and Programming will develop and lead Revolution Medicines' real-world analytics and programming capability, setting the strategy, operating model, technical standards, and priorities needed to generate rigorous, decision-ready real-world evidence across the product lifecycle. Reporting to the VP, HEOR/RWE, this leader will partner closely with the Executive Director, Head of Epidemiology & RWD Strategy to align RWD strategy, drive methodologic excellence and optimize the use of data for internal decision making and evidence generation.
Job description
Responsibilities
- Set and execute the enterprise strategy and multi-year roadmap for real-world analytics and programming in support of portfolio, Clinical Development, Safety, Medical Affairs, HEOR/RWE, and epidemiology priorities.
- Provide leadership of the cross-functional matrix delivering Medical Affairs interventional studies.
- Lead the assessment and fit-for-purpose use of RWD sources, including claims, electronic health records, registries, genomic/-omics data, and linked datasets.
- Provide scientific and operational leadership for RWE study design, protocol development, statistical analysis planning, programming, interpretation, and final reporting.
- Ensure delivery of evidence supporting regulatory submissions, product value, and critical development decisions, natural history studies, clinical trial design and optimization, comparative effectiveness and safety studies, healthcare resource utilization studies, post-approval safety studies, and rapid feasibility and landscape assessments.
- Establish fit-for-purpose epidemiologic, biostatistical, and data-science methods that ensure scientific rigor, reproducibility, and alignment with global regulatory guidance.
- Lead the development and adoption of scalable programming standards, reusable analytic assets, quality-control processes, and documentation practices.
- Partner with IT, data engineering, and other functions to define data requirements, establish data-ingestion and curation pipelines, and enable analytics environments and data-lake capabilities.
- Provide thought leadership in advanced analytic approaches, including causal inference, predictive modeling, and AI/ML.
- Translate complex analyses into clear, actionable insights and recommendations for executive leadership, regulatory agencies, payers, external collaborators, and scientific audiences.
- Lead and contribute to governance, portfolio, feasibility-review, and multidisciplinary teams.
- Build and lead a high-performing, multidisciplinary team; foster a strong talent and capability-development culture.
- Own functional resourcing, prioritization, and budget planning.
Required Skills, Experience and Education
- PhD, DSc, DrPH, MPH, or other relevant advanced degree in epidemiology, biostatistics, health outcomes, data science, or a related scientific discipline
- At least 15 years of progressively responsible experience in real-world analytics, programming, and evidence generation within pharmaceutical or biotechnology organizations
- Demonstrated success leading complex RWD/RWE programs from strategy through execution
- Demonstrated experience building, scaling, or transforming real-world analytics, programming, or data-science capabilities
- Strong expertise with RWD sources, including claims, EHR, registries, -omics data, and linked datasets
- Analytic tools such as R, SAS, and Python
- Demonstrated technical knowledge of epidemiologic, biostatistical, and data-science methods
- Knowledge of drug and clinical development processes for genomic/targeted medicines
- Excellent analytic and problem-solving skills
- Exceptional leadership, communication, and influence skills
Preferred Skills
- Experience in oncology real-world analytics and programming
- Track record of publications or presentations in real-world analytics and programming, epidemiology, or data science
- Experience aligning RWE strategy to regulatory and payer evidence planning
- Experience engaging with global regulatory authorities and interpreting evolving guidance relevant to RWD and RWE
- Demonstrated experience applying advanced analytic techniques, including causal inference, predictive modeling, and/or AI/ML
Requirements
- PhD, DSc, DrPH, MPH, or other relevant advanced degree in epidemiology, biostatistics, health outcomes, data science, or a related scientific discipline
- At least 15 years of progressively responsible experience in real-world analytics, programming, and evidence generation within pharmaceutical or biotechnology organizations
- Demonstrated success leading complex RWD/RWE programs from strategy through execution, including study design, analysis, programming, reporting, and regulatory submission support
- Demonstrated experience building, scaling, or transforming real-world analytics, programming, or data-science capabilities, including establishment of standards, processes, and cross-functional partnerships
- Strong expertise with RWD sources, including claims, EHR, registries, -omics data, and linked datasets, and analytic tools such as R, SAS, and Python
- Demonstrated technical knowledge of epidemiologic, biostatistical, and data-science methods
- Knowledge of drug and clinical development processes for genomic/targeted medicines
- Excellent analytic and problem-solving skills
- Exceptional leadership, communication, and influence skills, with the ability to work effectively across a complex matrix and shape senior-level decisions
Benefits
- Competitive cash compensation
- Robust equity awards
- Health benefits
- Learning and development opportunities
Company overview
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is pioneering a new class of therapeutics that target oncogenic RAS mutations, which are among the most common drivers of human cancers. Revolution Medicines employs a unique approach to drug discovery, leveraging deep insights into RAS biology to develop small molecule inhibitors that can address previously undruggable targets. Their pipeline includes multiple clinical-stage candidates designed to inhibit various RAS pathway mutations, with a particular focus on KRAS G12C and other RAS variants. The company's scientific platform combines structural biology, medicinal chemistry, and computational approaches to design highly selective inhibitors. Revolution Medicines aims to transform cancer treatment by developing therapies that can overcome resistance mechanisms and provide durable clinical benefits for patients with RAS-driven malignancies. Their research represents a significant advancement in the field of targeted cancer therapy, addressing one of the most challenging areas in oncology drug development.